Side-Effects Management

Managing Immune Checkpoint Inhibitor Side Effects: Key Recommendations

Clark Westfield

May 2018, Vol 8, No 5 - Side-Effects Management

Immunotherapies have transformed the treatment of cancer, but patients who receive immune checkpoint inhibitors may experience a range of side effects, which are only recently becoming familiar to oncologists and patients. The novelty of immune checkpoint inhibitors has led the American Society of Clinical Oncology (ASCO), in collaboration with the National Comprehensive Cancer Network (NCCN) to jointly develop a new guideline to help clinicians recognize and manage these side effects. [ Read More ]

Direct Oral Anticoagulants: New Standard of Care for VTE in Patients with Cancer?

Phoebe Starr

March 2018, Vol 8, No 3 - Side-Effects Management

Direct oral anticoagulants (DOACs) may soon replace low-molecular-weight heparin (LMWH) as the standard of care for the management of venous thromboembolism (VTE) in patients with cancer, judging by the results of 2 randomized trials presented at ASH 2017. The caveat is that DOACs are associated with more bleeding events, especially in patients with gastrointestinal (GI) cancer who should continue receiving LMWH. [ Read More ]

The Challenges of Oral Cancer Drugs Use and Side-Effects Management

Meg Barbor, MPH

February 2018, Vol 8, No 2 - Side-Effects Management

There is only one “king of the road” when it comes to dealing with the adverse side effects of oral cancer drugs, and that is not the healthcare professional, according to Christine B. Boers-Doets, MSc, of the Netherlands Leiden University Medical Center, author of The TARGET System, and creator of the 7 Pillars of Ultimate Drug Success formula. She discussed this topic at the recent ESMO International Consensus Conference for Advanced Breast Cancer in Lisbon, Portugal. [ Read More ]